Therapeutic drug monitoring

Blood tests that measure how much of a medicine (such as infliximab or adalimumab) is in your blood, and whether your body has made antibodies against it, so the dose can be adjusted.

Also called: tdm, drug levels, trough levels, drug level test, trough level, infliximab levels, adalimumab levels, drug monitoring

Related words anti-tnf anti-drug antibodies loss of response

Topics Monitoring Biologics and newer medicines

Questions people ask

Why does my team check drug levels and antibodies on infliximab or adalimumab?

Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.

Sources

Why might I be given azathioprine alongside infliximab?

The SONIC trial found that people who had not had these drugs before did better on infliximab plus azathioprine together than on either alone: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone. The European and UK guidelines draw on trials like this. Your team will discuss the extra monitoring and side effects of using two medicines.

Sources

Where to read more

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Feb 2021 For professionals

European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.

Topics Children and young people Medicines Diet and nutrition Biologics and newer medicines

Jargon explained paediatric penetrating disease stricturing disease exclusive enteral nutrition anti-TNF immunomodulator therapeutic drug monitoring

Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Aug 2026 For professionals

The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.

Topics Children and young people Diet and nutrition Biologics and newer medicines Monitoring

Jargon explained anti-TNF therapeutic drug monitoring exclusive enteral nutrition endoscopic remission

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (HTG401, formerly DG22)

NICE Guideline Feb 2016 For professionals

NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.

Topics Monitoring Biologics and newer medicines

Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF

Infliximab

Crohn's & Colitis UK Guide Jun 2024 For patients

A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.

Topics Biologics and newer medicines Monitoring

Jargon explained anti-TNF infusion subcutaneous biosimilar drug levels antibodies

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease

Frontline Gastroenterology (via PMC) Guide Nov 2025 For professionals

A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.

Topics Medicines Surgery Monitoring

Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity

Crohn's disease management after intestinal resection: a randomised trial (POCER)

The Lancet Study Feb 2015 For professionals

A trial of how to stop Crohn's returning after bowel surgery. Treating people according to their risk, checking with a colonoscopy at six months and stepping up treatment if the disease had come back worked better than standard drug treatment alone. It also showed that even low-risk patients need monitoring.

Topics Surgery Monitoring Research

Jargon explained post-operative recurrence colonoscopy step-up resection

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Search everything for "therapeutic drug monitoring"